Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound for treating sequelae of ischemic cerebral stroke

a technology of ischemic cerebral stroke and compound, which is applied in the direction of peptides/proteins, drug compositions, peptides, etc., can solve the problems of increasing the burden of disease, affecting the health of middle-aged and elderly people in china, and the inability to meet the metabolic requirement of local cerebral tissues by the available blood supply,

Active Publication Date: 2019-02-07
WANG JINGYI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The compound demonstrates therapeutic effects in reducing neurologic deficit scores and cerebral infarction injury rates in animal models, indicating its potential for effectively treating sequelae of ischemic cerebral stroke with reduced adverse effects.

Problems solved by technology

The fundamental cause of the ischemic cerebral stroke is that the extracranial or intracranial arteries leading to the brain have occlusive lesions and fail to achieve prompt and adequate collateral circulation so that the metabolism requirement of the local cerebral tissues cannot be met by the available blood supply.
Some severe cases result in death.
In particular, because of the improvement of medical conditions and the advancement of clinical technology, the mortality rate of stroke significantly declined while, however, leading to a great increase in the morbidity of the sequelae of cerebral stroke, which causes a greater disease burden.
The cerebral stroke has become a leading disease that jeopardizes the health of middle aged and elderly people in China.
Since a PVC infusion device has a significant absorption effect on butylphthalide, a PE infusion device can only be used for the infusion of the butylphthalide product.
There is no research data about the efficacy or safety of the drug administered 48 hours after the onset of the disease.
However, aspirin has no significant efficacy on the treatment of sequelae of ischemic cerebral stoke, but has multiple adverse effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for treating sequelae of ischemic cerebral stroke
  • Compound for treating sequelae of ischemic cerebral stroke
  • Compound for treating sequelae of ischemic cerebral stroke

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of the Compound of Formula (III)

1. Solid Phase Synthesis of Peptide Chain

[0066]100 g of dichloro-tritylchloride resin (having a degree of substitution, of 1 mmol / g resin) was added into a 5 L reaction flask, to which 1 L dichloromethane was added. After 10 minutes, the resin sufficiently swelled in the solution, and 31.08 g of Fmoc-Tyr(tBu)—OH were added followed by 38 ml of DIEA. The reaction was continued for 30 minutes. Then, 1500 ml of methanol was added to terminate the reaction. The resin was filtered off, washed successively with isopropanol (IPA), DMF, isopropanol, DMF, isopropanol and ethyl ether, and dried in a fume hood to constant weight.

[0067]100 g of dried resin carrying Fmoc-Tyr(tBu)—OH was added into a 2 L reaction flask, and 1 L of DMF was added so that the resin sufficiently swelled in the solvent of DMF. DMF was drawn under a negative pressure into a waste liquid bottle, and 1 L of piperidine / DMF solution (25%) was added. The reaction flask was placed on a shak...

example 2

[0084]Normal male SD rats, weighing 280-320 g, were used in six experiments on 1.5-hour ischemia / reperfusion model groups (I1.5R+ model). Monitoring the scores of neuroethology symptoms 24 hours after the cerebral ischemia reperfusion injury and at each subsequent week in rats of the 1.5-hours ischemia / reperfusion model groups. The final results and sample size: results from the I1.5R+ model group in six experiments were combined (animal data: 31 animals in total in the I1.5R+model groups. In addition, the data of first week was the combined data from the experimental groups and the model group, the animal number in the 24-hour data was 101, and the animal number in the first week, data was 106).

[0085]The weights and scores of SD rats in the 1.5-hour ischemia / reperfusion model were recorded at 1.0 different time points later. The results showed that the weights of SD rats in the 1.5-hour ischemia / reperfusion showed a tendency of gradually rising, and the neurological score of 24-hou...

example 3

[0086]Normal male SD rats, weighing 280-320 g, were used in three experiments. In the first experiment, animals were divided randomly into two groups, one group in which the administration started one week after the 1.5-hour ischemia / reperfusion and continued for four weeks (I1.5R+1 week+dosing for 4 weeks), and the other group for the 1.5-hour ischemia / reperfusion model without administering, the compound of formula (III) (I1.5R+model). In the second experiment, animals were divided randomly into two groups, one group in which the administration started two weeks after the 1.5-hour ischemia / reperfusion and continued for four weeks (I1.5R+2 weeks+dosing for 4 weeks), and the other group for the 1.5-hour ischemia / reperfusion model without administering, the compound of formula (III) (I1.5R+model).

[0087]In the third experiment, animals were divided randomly into two groups, one group in which the administration started three days after the 1.5-hour ischemia / reperfusion and continued f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention provides a compound (I) for treating sequelae of ischemic cerebral stroke:H—(NH—CHR1—CO)—(NH—CHR2—CO)—(NH—CHR3—CO)—(NH—CHR4—CO)—(NH—CHR5—CO)—(NH—CHR6—CO)—(NH—CHR7—CO)—OH  (I)or a pharmaceutically acceptable salt thereof, wherein R1-R7 are defined herein. The present invention also provides a pharmaceutical composition comprising said compound and use of the same in the manufacture of a medicament for treating sequelae of ischemic cerebral stroke. The compound and pharmaceutical composition according to the present invention have good pharmacological activities so that they are able to improve significantly the symptom of sequelae of ischemic cerebral stroke.

Description

RELATED APPLICATIONS[0001]This application is a divisional of U.S. Non-Provisional patent application Ser. No. 15 / 236,055, filed Aug. 12, 2016, which claims the benefit of priority to-International Patent Application No. PCT / CN2015 / 087048, filed Aug. 14, 2015, which are incorporated by reference herein in their entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 8, 2018, is named 2018-08-08_W103046_1010 USD1_SequenceListing.txt and is 917 bytes in size.TECHNICAL FIELD[0003]The present invention relates to a medicinal compound for treating sequelae of ischemic cerebral stroke and the use of the same in the manufacture of a medicament for treating sequelae of ischemic cerebral stroke.BACKGROUND ART[0004]Cerebral stroke is a disease in which a cerebral tissue damage is caused by a sudden blood vessle rupture or by ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K7/06A61K38/08A61K38/00
CPCA61K38/00A61K38/08C07K7/06A61K31/417C07D233/64A61P9/10
Inventor WANG, JINGYIZUO, JIANLINGLV, XIAOLIANGZHANG, TAN
Owner WANG JINGYI